1
|
Paasch U, Zidane M, Baron JM, Bund T, Cappius HJ, Drosner M, Feise K, Fischer T, Gauglitz G, Gerber PA, Grunewald S, Herberger K, Jung A, Karsai S, Kautz G, Philipp C, Schädel D, Seitz AT, Nast A. S2k guideline: Laser therapy of the skin. J Dtsch Dermatol Ges 2022; 20:1248-1267. [PMID: 36098675 DOI: 10.1111/ddg.14879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
This guideline aims to improve the efficiency and safety of lasers and optical radiation sources with similar effects (especially IPL). Laser therapy of skin lesions with an increased amount of melanocytes should be performed with caution. Laser treatment of pigmented melanocytic nevi is not recommended. The guideline contains recommendations regarding the treatment of lentigines and café-au-lait spots, non-pigmented dermal nevi, Becker nevus, nevus of Ota/Hori/Ito and melasma. Further recommendations focus on the treatment of skin lesions without an increased amount of melanocytes (ephelides, postinflammatory hyperpigmentation including berloque dermatitis, seborrheic keratoses, traumatic/decorative tattoos and metallic deposits), hypopigmentation (vitiligo), benign non-pigmented neoplasms (fibrous papule of the nose, nevus sebaceus, epidermal nevus, neurofibroma, sebaceous gland hyperplasia, syringoma, xanthelasma palpebrarum), inflammatory dermatoses (acne papulopustulosa/conglobata, acne inversa, granuloma faciale, lichen sclerosus, lupus erythematosus, psoriasis vulgaris, rosacea, rhinophyma), wrinkles/dermatochalasis/striae, hypertrichosis, scars (atrophic, hypertrophic; keloids, burn/scald scars), laser-assisted skin healing, onychomycosis, precancerous lesions and malignant tumors (actinic keratoses/field cancerization, cheilitis actinica, basal cell carcinoma), vascular skin lesions (angiokeratoma, angioma, hemangioma, malformation, spider veins, granuloma telangiectaticum (pyogenic granuloma), rubeosis (erythrosis interfollicularis colli, ulerythema ophryogenes), nevus flammeus, telangiectasias and Osler's disease (hereditary hemorrhagic telangiectasia) and viral skin lesions (condylomata acuminata, mollusca contagiosa, verrucae planae juveniles/vulgares/ verrucae palmares et plantares).
Collapse
Affiliation(s)
- Uwe Paasch
- Hautaerzte Paasch, Practice Prof. Paasch, Jesewitz OT Gotha, Germany, University Hospital Leipzig, Department and Clinic for Dermatology, Venereology and Allergology, Leipzig
| | - Miriam Zidane
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Dermatology, Venereology and Allergology, Division of Evidence-Based Medicine (dEBM), Berlin
| | - Jens Malte Baron
- University Hospital Aachen, Department for Dermatology and Allergology - Skin Medicine, Aachen
| | - Thorsten Bund
- Department for Plastic, Esthetic, and Reconstructive Microsurgery, Hand Surgery at Ernst von Bergmann Hospital, Potsdam
| | | | - Michael Drosner
- Skin & Laser Schwerin, Skin & Laser Rostock, Schwerin and Rostock
| | | | - Tanja Fischer
- Skin & Laser Center Berlin-Potsdam, Berlin and Potsdam
| | - Gerd Gauglitz
- Skin and Laser Center Glockenbach Quarter, Munich, Department for Dermatology and Allergology, Ludwig-Maximilians University, Munich
| | - Peter Arne Gerber
- Dermatology at Luegplatz, Düsseldorf, Department for Dermatology, Medical Faculty, Heinrich-Heine University, Düsseldorf
| | - Sonja Grunewald
- University Hospital Leipzig, Department and Clinic for Dermatology, Venereology and Allergology, Leipzig
| | - Katharina Herberger
- University Hospital Hamburg-Eppendorf (UKE), Department for Dermatology and Venereology, Hamburg
| | - Anja Jung
- Center for Proctology, Evangelisches Elisabeth Hospital, Berlin, Deutschland
| | | | - Gerd Kautz
- Skin and Laser Hospital Dres. Gerd and Ingrid Kautz, Konz
| | - Carsten Philipp
- Center Laser Medicine, Evangelisches Elisabeth Hospital, Berlin
| | | | - Anna-Theresa Seitz
- University Hospital Leipzig, Department and Clinic for Dermatology, Venereology and Allergology, Leipzig
| | - Alexander Nast
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Dermatology, Venereology and Allergology, Division of Evidence-Based Medicine (dEBM), Berlin
| |
Collapse
|
2
|
Paasch U, Zidane M, Baron JM, Bund T, Cappius HJ, Drosner M, Feise K, Fischer T, Gauglitz G, Gerber PA, Grunewald S, Herberger K, Jung A, Karsai S, Kautz G, Philipp C, Schädel D, Seitz AT, Nast A. S2k-Leitlinie: Lasertherapie der Haut. J Dtsch Dermatol Ges 2022; 20:1248-1270. [PMID: 36162017 DOI: 10.1111/ddg.14879_g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- Uwe Paasch
- Hautärzte Paasch, Praxis Prof. Paasch, Jesewitz OT Gotha, Deutschland, Universitätsklinikum Leipzig, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Leipzig
| | - Miriam Zidane
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Klinik für Dermatologie, Venerologie und Allergologie, Division of Evidence-Based Medicine (dEBM), Berlin
| | - Jens Malte Baron
- Universitätsklinikum Aachen, Klinik für Dermatologie und Allergologie - Hautklinik, Aachen
| | - Thorsten Bund
- Klinik für Plastische, Ästhetische und Rekonstruktive Mikrochirurgie, Handchirurgie am Klinikum Ernst von Bergmann, Potsdam
| | | | - Michael Drosner
- Haut & Laser Schwerin, Haut & Laser Rostock, Schwerin und Rostock
| | | | - Tanja Fischer
- Haut- & Lasercentrum Berlin-Potsdam, Berlin und Potsdam
| | - Gerd Gauglitz
- Haut- und Laserzentrum im Glockenbachviertel, München, Klinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität, München
| | - Peter Arne Gerber
- Dermatologie am Luegplatz, Düsseldorf, Klinik für Dermatologie, Medizinische Fakultät, Heinrich-Heine-Universität, Düsseldorf
| | - Sonja Grunewald
- Universitätsklinikum Leipzig, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Leipzig
| | - Katharina Herberger
- Universitätsklinikum Hamburg-Eppendorf (UKE), Klinik für Dermatologie und Venerologie, Hamburg
| | - Anja Jung
- Zentrum Proktologie, Evangelische Elisabeth Klinik, Berlin, Deutschland
| | | | - Gerd Kautz
- Haut- und Laserklinik Dres. Gerd und Ingrid Kautz, Konz
| | | | | | - Anna-Theresa Seitz
- Universitätsklinikum Leipzig, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Leipzig
| | - Alexander Nast
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Klinik für Dermatologie, Venerologie und Allergologie, Division of Evidence-Based Medicine (dEBM), Berlin
| |
Collapse
|
3
|
MITSUISHI TSUYOSHI, SASAGAWA TOSHIYUKI, KATO TOSHIHIKO, IIDA KAZUMI, UENO TAKASHI, IKEDA MASUMI, NINOMIYA RISA, WAKABAYASHI TOSHITERU, KAWASAKI HIROFUMI, MOTOKI TOMOTERU, KAWANA SEIJI. Combination of Carbon Dioxide Laser Therapy and Artificial Dermis Application in Plantar Warts: Human Papillomavirus DNA Analysis after Treatment. Dermatol Surg 2010; 36:1401-5. [DOI: 10.1111/j.1524-4725.2010.01648.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
4
|
Yang J, Pu YG, Zeng ZM, Yu ZJ, Huang N, Deng QW. Interferon for the treatment of genital warts: a systematic review. BMC Infect Dis 2009; 9:156. [PMID: 19772554 PMCID: PMC2754484 DOI: 10.1186/1471-2334-9-156] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2009] [Accepted: 09/21/2009] [Indexed: 11/12/2022] Open
Abstract
Background Interferon has been widely used in the treatment of genital warts for its immunomodulatory, antiproliferative and antiviral properties. Currently, no evidence that interferon improves the complete response rate or reduces the recurrence rate of genital warts has been generally provided. The aim of this review is to assess, from randomized control trials (RCTs), the efficacy and safety of interferon in curing genital warts. Methods We searched Cochrane Sexually Transmitted Diseases Group's Trials Register (January, 2009), Cochrane Central Register of Controlled Trials (2009, issue 1), PubMed (1950-2009), EMBASE (1974-2009), Chinese Biomedical Literature Database (CBM) (1975-2009), China National Knowledge Infrastructure (CNKI) (1979-2009), VIP database (1989-2009), as well as reference lists of relevant studies. Two reviewers independently screened searched studies, extracted data and evaluated their methodological qualities. RevMan 4.2.8 software was used for meta-analysis Results 12 RCTs involving 1445 people were included. Among them, 7 studies demonstrated the complete response rate of locally-used interferon as compared to placebo for treating genital warts. Based on meta-analysis, the rate of Complete response of the two interventions differed significantly (locally-used interferon:44.4%; placebo:16.1%). The difference between the two groups had statistical significance (RR 2.68, 95% CI 1.79 to 4.02, P < 0.00001). 5 studies demonstrated the complete response rate of systemically-used interferon as compared to placebo for treating genital warts. Based on meta-analysis, the rate of Complete response of the two interventions had no perceivable discrepancy (systemically-used interferon:27.4%; placebo:26.4%). The difference between the two groups had no statistical significance (RR1.25, 95% CI 0.80 to 1.95, P > 0.05). 7 studies demonstrated the recurrence rate of interferon as compared to placebo for treating genital warts. Based on meta-analysis, the recurrence rate of the two interventions had no perceivable discrepancy(interferon 21.1%; placebo: 34.2%). The difference between the two groups had no statistical significance (RR0.56, 95% CI 0.27 to 1.18, P > 0.05). However, subgroup analysis showed that HPV-infected patients with locally administered interferon were less likely than those given placebo to relapse, but that no significant difference in relapse rates was observed between systemic and placebo. The reported adverse events of interferon were mostly mild and transient, which could be well tolerated. Conclusion Interferon tends to be a fairly well-tolerated form of therapy. According to different routes of administration, locally-used interferon appears to be much more effective than both systemically-used interferon and placebo in either improving the complete response rate or reducing the recurrence rate for the treatment of genital warts.
Collapse
Affiliation(s)
- Jin Yang
- Department of Infectious Diseases, Nanshan Affiliated Hospital of Guangdong Medical College, Shenzhen 518052, PR China
| | | | | | | | | | | |
Collapse
|
5
|
Tchernev G. Sexually transmitted papillomavirus infections: epidemiology pathogenesis, clinic, morphology, important differential diagnostic aspects, current diagnostic and treatment options. An Bras Dermatol 2009; 84:377-89. [DOI: 10.1590/s0365-05962009000400009] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
The family of human papilloma viruses (HPV) comprises more than 100 genotypes. Approximately 30 of the genotypes are responsible for infections in the human anogenital area. A precisely defined algorithm with the goal of diagnosing and removing HPV for a prolonged or indefinite length of time, as well as to protect the patient from any malignant ransformation, does not currently exist. The identification of HPV strains by PCR or DNA hybridization in lesional tissue provides higher security for the patients. In high-risk patients additional colposcopy, rectoscopy, and rethroscopy/cystoscopy increase the probability of proper diagnosis and the application of a reliable therapeutic strategy. Removal of lesions by means of invasive methods, such as electrodessication, cryosurgery, and/or laser therapy, may be successful and could be combined pre- and postoperatively with the local application of podophyllotoxin, Trichloroacetic acid, 5-fluorouracil epinephrine gel, imiquimod, cidofovir or interferon. The administration of vaccine to young patients prevents to a significant extent the clinical manifestation of the most frequent viral strains, being HPV-6,-11 and -18. The different therapeutic methods must be applied in accordance with the clinical picture, taking into account the patient's general status, the presence of concomitant diseases, as well as the local and systematic compatibility of the side effects of each remedy. The review focuses on the diagnosis and treatment options of sexually transmitted HPV-infections and includes synopsis of the most recent literature regarding new data of epidemiology, pathogenesis, ifferential diagnosis and morphology of HPV infections in humans.
Collapse
|
6
|
|
7
|
Abstract
The CO2 laser is a versatile and effective tool for the treatment of warts and various other epidermal and dermal lesions where there is no easily targeted chromophore other than water. The development of high peak-power short-pulsed or rapidly scanned resurfacing CO2 lasers has significantly improved the safety and efficacy of this treatment modality. Many lesions amenable to CO2 laser vaporization, however, can be treated by other, far less expensive methods, and it is the laser surgeon's responsibility to use the CO2 laser only when it is demonstrably the best treatment option. The pulsed dye laser has some utility for selected recalcitrant warts. Because of their greater safety margin and more precise ablation, resurfacing CO2 and Er:YAG lasers are replacing the continuous wave CO2 laser for the ablation of many superficial lesions.
Collapse
Affiliation(s)
- George J Hruza
- Departments of Dermatology and Otolaryngology/Head and Neck Surgery, Saint Louis University School of Medicine, Laser & Dermatologic Surgery Center, St. Louis, Missouri, USA.
| |
Collapse
|
8
|
|
9
|
Abstract
BACKGROUND Human papillomaviruses (HPV) are common human pathogens and are classified into more than 80 different types. These viruses produce benign warts in many cases and aggressive squamous cell carcinomas in other cases. OBJECTIVE The goal of this review is to update the reader on the epidemiology, pathogenesis, and therapy of HPV infections. Nonanogenital warts are transmitted by skin-to-skin contact while anogenital warts are usually transmitted sexually. Both types of warts produce much morbidity but rarely undergo malignant transformation. They are commonly treated with surgical or cytodestructive therapy, but immunomodulatory agents, such as imiquimod, have been proven to be very effective in anogenital warts and are being evaluated in nonanogenital warts. Other types of HPV have marked oncogenic potential such that over 99% of all cervical cancers and over 50% of other anogenital cancers are due to infection with oncogenic HPV. Many cofactors, such as cigarette smoking, genetics, and helper viruses, have potential roles in HPV oncogenesis, but their relative contributions are poorly understood. Other control measures for warts and HPV-associated cancers are under study, but the greatest future potential may be from the development of prophylactic and therapeutic vaccines. CONCLUSIONS Infection with HPV is very prevalent as are the clinical manifestations of this family of pathogens. Improved therapies for warts (e.g., imiquimod) have recently become available. Vaccines for HPV offer hope for future interventions for warts as well as for prevention of anogenital malignancies.
Collapse
Affiliation(s)
- J Severson
- Department of Dermatology, University of Texas Medical Branch, Galveston 77058, USA
| | | | | | | | | | | |
Collapse
|
10
|
Abstract
Human papillomavirus (HPV) is a DNA-containing virus associated with a wide variety of clinical and subclinical diseases. These HPV lesions may resolve spontaneously or progress to benign (condyloma acuminata) or malignant (genital carcinoma) neoplasms. The incidence of HPV genital infection has risen dramatically over the past 30 years, and it is now the most common viral sexually transmitted disease. Many therapeutic options are available to the urologist with new treatments currently being investigated. The history, etiology, pathogenesis, carcinogenesis, and guidelines for evaluation and management are discussed.
Collapse
Affiliation(s)
- P A Pinto
- Department of Urology, Long Island Jewish Medical Center, New Hyde Park, New York, USA
| | | |
Collapse
|
11
|
Bohle A, Doehn C, Kausch I, Jocham D. TREATMENT OF RECURRENT PENILE CONDYLOMATA ACUMINATA WITH EXTERNAL APPLICATION AND INTRAURETHRAL INSTILLATION OF BACILLUS CALMETTE-GUERIN. J Urol 1998. [DOI: 10.1097/00005392-199808000-00028] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
12
|
BOHLE A, DOEHN C, KAUSCH I, JOCHAM D. TREATMENT OF RECURRENT PENILE CONDYLOMATA ACUMINATA WITH EXTERNAL APPLICATION AND INTRAURETHRAL INSTILLATION OF BACILLUS CALMETTE-GUERIN. J Urol 1998. [DOI: 10.1016/s0022-5347(01)62906-9] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- A. BOHLE
- Department of Urology, Medical University of Lubeck, Lubeck, Germany
| | - C. DOEHN
- Department of Urology, Medical University of Lubeck, Lubeck, Germany
| | - I. KAUSCH
- Department of Urology, Medical University of Lubeck, Lubeck, Germany
| | - D. JOCHAM
- Department of Urology, Medical University of Lubeck, Lubeck, Germany
| |
Collapse
|
13
|
Abstract
The CO2 laser is a versatile and effective tool for the treatment of warts and various other epidermal and dermal lesions where there is no easily targeted chromophore other than water. The development of high peak power, short-pulse, or rapidly scanned resurfacing CO2 lasers has significantly improved the safety and efficacy of using the CO2 laser. Many lesions amenable to CO2 laser vaporization can be treated by other far less expensive treatment modalities, however, and it is the laser surgeon's responsibility to use the CO2 laser only in cases in which it is demonstrably the best treatment option. The pulsed dye laser may replace the CO2 laser for the treatment of recalcitrant warts if the impressive early cure rates reported are borne out over time. Newer laser systems such as the Er:YAG laser with its extremely small zone of thermal damage may supplant the CO2 laser in the treatment of other epidermal and dermal lesions in the future.
Collapse
Affiliation(s)
- G J Hruza
- Department of Medicine (Dermatology), Washington University School of Medicine, St. Louis, Missouri, USA
| |
Collapse
|
14
|
Affiliation(s)
- N L Sykes
- Department of Dermatology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, USA
| |
Collapse
|
15
|
Abstract
BACKGROUND The treatment of palmar and plantar warts is difficult and often frustrating. The need for multiple destructive treatments and recurrences after apparent cure are common. OBJECTIVE The purpose of this study was to determine if intralesional natural alpha interferon might offer an effective alternative therapy for common plantar and palmar warts. METHODS A series of 22 private office patients with palmar and plantar warts were treated with intralesional natural alpha interferon using a needless injector. We treated twice weekly for a minimum of 8 weeks or until clear. RESULTS Sixteen patients (73%) showed complete clearing of their warts in a mean of 11 weeks of twice weekly treatment. Upon follow-up, which averaged 9.5 months, 17 of 21 patients (81%) remained clear of their warts. CONCLUSION Natural alpha interferon by needless injector appears to represent an effective alternative treatment for palmar and plantar human papillomavirus lesions. Further study of this modality is indicated.
Collapse
Affiliation(s)
- R T Brodell
- Northeastern Ohio Universities College of Medicine, Rootstown, USA
| | | |
Collapse
|
16
|
Abstract
PURPOSE The aim of this study was to determine whether interferon combined with surgical excision and fulguration could reduce the unacceptably high rate of recurrence of anal condyloma seen after surgical extirpation. METHODS Forty-three patients with anal condyloma were prospectively randomized into two groups. Group I (n = 25) patients underwent surgical excision and fulguration immediately followed by an injection of 500,000 IU (0.1 ml) of interferon alfa-n3 into each quadrant of the anal canal. Group II (n = 18) patients underwent surgical excision and fulguration but then received four injections (0.1 ml) of saline into each quadrant of the anal canal. RESULTS After a mean follow-up of 3.8 months, 10 of 43 (23 percent) patients developed recurrent anal condyloma. Only 3 of 25 (12 percent) interferon-treated patients had recurrences vs. 7 recurrences in 18 (39 percent) saline-treated patients (P = 0.046). Interferon was particularly effective in reducing recurrences in patients whose condylomata were present for more than six months (P = 0.04) and those condylomata that contained human papillomavirus DNA subtype 6/11 (P = 0.05). CONCLUSION Adjuvant interferon treatment can reduce the high recurrence rate of anal condyloma seen after surgical extirpation.
Collapse
Affiliation(s)
- P R Fleshner
- Division of Colon and Rectal Surgery, Cedars-Sinai Medical Center, Los Angeles, California
| | | |
Collapse
|
17
|
Olmos L, Vilata J, Rodríguez Pichardo A, Lloret A, Ojeda A, Calderón MD. Double-blind, randomized clinical trial on the effect of interferon-beta in the treatment of condylomata acuminata. Int J STD AIDS 1994; 5:182-5. [PMID: 8061088 DOI: 10.1177/095646249400500305] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
A randomized, double-blind, placebo-controlled trial was conducted to assess interferon-beta efficacy and safety in the treatment of anogenital condylomatous lesions. One hundred patients received a daily intramuscular injection of either interferon-beta (IFN-beta) (2 MIU/day) or placebo for 10 days. Of 94 evaluable patients, the complete response rate observed 8 weeks after treatment was significantly higher in the group receiving IFN-beta, as compared to the placebo-treated group (51% vs 28.9%, P < 0.05). After one year, 24 patients (100%) out of 24 complete responders to IFN-beta who attended for follow-up remained free of lesions. Twelve of 13 patients with complete response to placebo (92.3%) remained free of lesions after one year. Side effects were mild and no significant analytical changes were observed. In conclusion, interferon-beta is an effective and safe treatment for long-term eradication of anogenital condylomatous lesions.
Collapse
Affiliation(s)
- L Olmos
- Department of Dermatology, Hospital Clínico Universitario San Carlos, Madrid, Spain
| | | | | | | | | | | |
Collapse
|